摘要
目的探讨辛伐他汀联合低分子肝素治疗肾病综合征的临床疗效及其安全性。方法选取乐平市中医医院2017年8月-2018年8月收治的肾病综合征患者70例,随机分为参照组和研究组,各35例。参照组给予常规治疗,研究组给予辛伐他汀联合低分子肝素治疗。两组均连续治疗4周。比较两组临床疗效,凝血功能指标〔凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原含量(FIB)〕和生化指标〔24 h尿蛋白、血清白蛋白、总胆固醇和三酰甘油〕,并观察两组不良反应发生情况。结果研究组总有效率高于参照组(P<0.05)。研究组PT、APTT和TT长于参照组,FIB低于参照组(P<0.05)。研究组24 h尿蛋白、总胆固醇和三酰甘油低于参照组,血清白蛋白高于参照组(P<0.05)。两组治疗期间均未出现出血等不良反应。结论辛伐他汀联合低分子肝素治疗肾病综合征的临床疗效确切,可改善患者高凝状态,降低血脂和血液黏度,且安全性高。
Objective To explore the clinical efficacy and safety of simvastatin combined with low molecular weight heparin for nephrotic syndrome.Methods A total of 70 cases of patients with nephrotic syndrome were selected from August 2017 to August 2018 in Leping Hospital of Traditional Chinese Medicine,which were randomly divided into the reference group and the study group,35 cases in each group.The reference group was given conventional treatment,the study group was given simvastatin combined with low molecular weight heparin treatment.Both groups were treated for 4 weeks.The clinical effects of the two groups were compared,coagulation function indexes(PT,APTT,TT,FIB)and biochemical indexes(24 h urine protein,serum albumin,total cholesterol and triacylglycerol).The adverse reactions of the two groups were observed.Results The total effective rate of the study group was higher than the reference group(P<0.05).The study group of the PT,APTT and TT were longer than the reference group,FIB was lower than the reference group(P<0.05).The study group of the 24 h urine protein,total cholesterol and triacylglycerol were lower than the reference group,serum albumin was higher than the reference group(P<0.05).No bleeding and other adverse reactions occurred in the two groups.Conclusion Simvastatin combined with low molecular weight heparin has definite clinical effect for nephrotic syndrome,it can improve the hypercoagulable state of patients,reduce blood lipid and blood viscosity,and with high safety.
出处
《临床合理用药杂志》
2019年第33期1-2,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
肾病综合征
辛伐他汀
低分子肝素
临床疗效
Nephrotic syndrome
Simvastatin
Low molecular weight heparin
Clinical efficacy
